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ABSTRACT
The cyclin-dependent kinase inhibitor 1A (CDKN1A),
also known as p21 (WAF1/CIP1) modulates cell cycle,
apoptosis, senescence and differentiation via spe-
cific protein–protein interactions with the cyclins,
cyclin-dependent kinase (Cdk), and many others.
Expression of the p21 gene is mainly regulated
at the transcriptional level. By conducting both
ligation-mediated PCR (LMPCR) and chromatin
immunoprecipitation (ChIP) in vivo, we identified a
functional target site for the transcription factor,
nuclear factor I (NFI), in the basal promoter from the
p21 gene. Transfection of recombinant constructs
bearing mutations in the p21 NFI site demonstrated
that NFI acts as a repressor of p21 gene expression
in various types of cultured cells. Inhibition of NFI
in human skin fibroblasts through RNAi considera-
bly increased p21 promoter activity suggesting that
NFI is a key repressor of p21 transcription. Over-
expression of each of the four NFI isoforms in
HCT116 cells established that each of them con-
tribute to various extend to the repression of the
p21 gene. Most of all, over-expression of NFI-B in
doxorubicin, growth-arrested HCT116 increased the
proportion of cells in the S-phase of the cell cycle
whereas NFI-A and NFI-X reduced it, thereby estab-
lishing a role for NFI in the cell cycle dependent
expression of p21.
INTRODUCTION
p21 (CDKN1A) belongs to a family of cell-cycle dependent
kinase inhibitors. p21 modulates various processes such
as cell growth (1), differentiation (2) and apoptosis (3).
DNA-damaging agents such as UV-irradiations or carcino-
gens induce the transcriptional activation of p21 via a p53-
dependent pathway. Phosphorylated p53 binds to regulatory
elements present in distal regions of the p21 promoter and
transactivates p21 transcription via physical and functional
interactions with the ubiquitous transcription factor Sp1
bound to the proximal region (4,5). Strong p21 accumulation
lead to suppression of cdk activity, allowing the accumulation
of hypophosphorylated Rb, inhibition of E2F-dependent tran-
scriptional processes, and cell cycle arrest in G1 (6–8). By
interacting directly with PCNA, an auxiliary factor for
DNA polymerases d and e, p21 also prevents DNA synthesis
and regulates DNA methylation without alteration of the
PCNA-dependent nucleotide-excision repair (9,10). Some
reports also suggest a p53-independent activation of p21
following UV-irradiation (11,12) but the mechanisms of
induction remained poorly understood. Inducers of differen-
tiation such as steroid hormones (13), transforming growth
factor-b (TGF-b), phorbol ester or phosphatase inhibitors
(14), interferon g (15), progesterone (16), nerve growth factor
(17) and platelet-derived growth factor (18) enhance p21
gene expression in many different cell systems. As for p53,
the majority of these modulators affect p21 gene transcription
via Sp1 and Sp3 interactions at the proximal promoter.
Novel alternate p21 transcripts that are upregulated as a result
of DNA damage-induced p53 activation and are dependent
on p53 for their basal or induced expression were recently
discovered (19,20).
In proliferating cells, p21 is expressed at a basal level in a
constitutive and cell cycle dependant way (21). Under these
conditions, most of the p21 proteins are components of the
cyclin/cdk active complex (22). Therefore, it is likely that
p21, when expressed at a moderate level, can act as an anchor
protein as well as an assembly factor for cyclin D-cdk4/cdk6
thereby promoting their mutual interactions and consequently
cell cycle progression, which is in complete contrast to its
function as a cdk inhibitor (23). However, there seems to
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involved in this basal expression of the p21 gene. In this
study, we provided evidence that NFI is a major contributor
of p21 gene expression as it could repress its transcription
by interacting with the p21 proximal promoter in vivo.
MATERIALS AND METHODS
Cell culture
Human skin ﬁbroblasts (HSFs) were isolated from skin biops-
ies of healthy male donors and primary cultured in DMEM
(Gibco BRL, Burlington, ON, Canada) supplemented with
10% fetal bovine serum (FBS, Gibco BRL). Human epith-
eloid carcinoma HeLa cells (ATCC CCL 2) were grown in
DMEM supplemented with 10% FBS. Rat pituitary GH4C1
cells were grown in Ham’s F10 medium (Sigma-Aldrich,
Oakville, ON, Canada) supplemented with 10% FBS. The
human colorectal cancer cell line HCT116, kindly donated
by Dr Chantal Guillemette (Oncology and Molecular Endo-
crinology Research Center, CHUL, Que ´bec, Canada), was
grown in McCoy’s medium (Invitrogen cat# 16600) supple-
mented with 10% FBS. All cells were grown under 5%
CO2 at 37 C and gentamycin was added to all media at a
ﬁnal concentration of 15 mg/ml.
Cell cycle analysis
HCT116 cells (2.5 · 10
5 cells/well) were plated into 6-wells
tissue culture plates (Sarstedt, Montre ´al, QC, Canada) in
complete McCoy’s medium and then growth arrested by the
addition of 500 nM doxorubicin (Sigma-Aldrich). Approxi-
mately 48 h later, cells were collected, ﬁxed with 70% cold
ethanol, and stored at –20 C overnight. Fixed cells were
washed with PBS and incubated with PBS containing
RNase (100 mg/ml) and PI (10 mg/ml) at room temperature
in the dark for 30 min. The DNA content of the cells were
analyzed using ﬂow cytometry and acquisition of data for
10
5 events were performed using an Epics XL ﬂow cytometer
(Beckman Coulter, Miami, FL). The distribution of HCT116
cells within each phase of the cell cycle was analyzed from
dual parameters histograms using an Epics  Elite ﬂow
cytometry workstation version 4.5 software.
In vivo footprinting
HSFs were seeded into 150 mm culture plates at a density of
50% cells/plate and grown as above for 3 days. Living cells
and puriﬁed DNA (referred as in vivo and in vitro, respec-
tively) were treated with one of the following probing agents:
0.02% dimethylsulphate (DMS; Sigma-Aldrich Canada),
ultraviolet C (UVC; 1500 J/m
2) irradiation (G15T8 germi-
cidal lamp; Philips, Montreal, QC, Canada) and DNase I
(8.75 g/ml; Worthington Biochemical, Lakewood, NJ, USA)
as previously described (24,25). Strand break frequencies
were estimated on an alkaline agarose gel. LMPCR was
carried out as previously described (24,25) using two primer
sets (1A: 50-TCTCTCACCTCCTCTGA-30, position +97 to
+81; 1B: 50-CTGAGTGCCTCGGTGCCTCGGCG-30, posi-
tion +85 to +62; and 2A: 50-CCAGA TTTGTGGCTCAC-
30, position  280 to  264; 2B: 50CTCACTTCGGGGGAAA-
TGTGTCCAGCG-30; position  268 to  241), allowing the
analysis of the proximal promoter of p21 from nt  220 to
+40. Brieﬂy, gene-speciﬁc primers were annealed to the
genomic fragments of varying sizes and then extended
using cloned Pfu exo-DNA polymerase (Stratagene, LaJolla,
CA) to produce double-strand blunt ends. An asymmetric
double-strand linker (L25: 50-GCGGTGACCCGGGAGAT-
CTG-AATTC-30 and oligo L11: 50-GAATTCAGATC-30)
was then ligated to the phosphorylated terminal end of
each fragment, providing a common sequence on the 50 end
of all fragments. Using Pfu exo-DNA polymerase, a linker-
speciﬁc primer was used for a single round of linear ampli-
ﬁcation, followed by PCR ampliﬁcation using the appropriate
primer sets in combination with the linker primer. All primer
extensions and PCR ampliﬁcations were carried out on T gra-
dient thermocycler from Biometra (Montreal Biotech, Inc.
Kirkland, Canada) as described (24,25). The PCR-ampliﬁed
fragments were phenol/chloroform extracted, ethanol precipi-
tated and subjected to electrophoresis on 8% polyacrylamide,
7 M urea gels alongside a Maxam and Gilbert sequencing
ladder, followed by electrotransfer to nylon membranes
(Roche Diagnostics Corp., Laval, Canada), hybridization to
a
32P-labeled gene-speciﬁc probe and visualization by auto-
radiography on Kodak ﬁlms (Amersham Biosciences, Baie
d’Urfe ´, Canada).
Plasmid constructs
The p21 promoter fragment spanning region  192 to +36
(p21–192) relative to the mRNA start site was produced
by KpnI/BglII digestion of the plasmid p21 (0–2300)-Luc
containing the entire p21 promoter (kindly provided by
Dr Claude Labrie, Oncology and Molecular Endocrinology
Research Center, CHUL Research Center, Que ´bec, Canada).
Synthetic oligomers were used to produce two distinct link-
ers allowing the ligation of the fragment upstream of the
chloramphenicol acetyltransferase (CAT) reporter gene in
the HindIII/XbaI-linearized vector pCATbasic (Promega,
Madison, WI). The plasmid lacking the region  192 to
 125 (p21–124) was obtained through double-digestion of
the p21–192 construct with the KpnI and BstX1 restriction
enzymes. The p21–192 mNFI construct that bear a mutated
NFI binding site was produced by the PCR, using p21–192
as a template and the synthetic oligomers p21-NFImA/B
(50-GGACCGGCTGGCCTGCTAAAACTCGATTAGGCTC-
AGCTGGCTCC-30)/(50-GGAGCCAGCTGAGCCTAATC-
GAGTTTTAGCAGGCCACCGGTCC-30). PCR ampliﬁcations
were performed using the QuickChange  Site-Directed
Mutagenesis Kit (Stratagene) according to the manufacturer’s
speciﬁcations. The DNA insert from each recombinant plas-
mid was sequenced by chain-termination dideoxy sequencing
(26) to conﬁrm the mutations. The pCH-NFI-A1.1,
pCH-NFI-B, pCH-NFI-C and pCH-NFI-X expression plas-
mids that encode high levels of the NFI-A, -B, -C and -X
NFI isoforms, as well as the empty vector pCH that was
used to derive the NFI expressing plasmids have been kindly
provided by Dr Richard M. Gronostajski (Department of
Biochemistry, SUNY at Buffalo, Buffalo, NY, USA).
Protein extracts and electrophoretic mobility
shift assays
Nuclear extracts from primary cultured HSFs deprived or not
of serum for 48–72 h, or from rat pituitary GH4C1 and HeLa
Nucleic Acids Research, 2006, Vol. 34, No. 22 6473cells were prepared as described previously (27,28) and kept
frozen at  80 C until use. The NFI-L-enriched rat liver
carboxymethyl (CM)-Sepharose fraction has been described
previously (29). The protein concentration was determined
for each nuclear extract by the Bradford procedure and
further validated by Coomassie blue staining of SDS–poly-
acrylamide fractionated nuclear proteins. Double-stranded
synthetic oligonucleotides corresponding to: (i) the p21 pro-
moter region located from  167 to  127 and bearing the
target region for NFI (p21.1: 50-GCCTGCTGGAACTCGG-
CCAGGCTCAGCTGGCTCCGCGCGG-30), (ii) the high-
afﬁnity binding site for CTF/NFI (50-GATCTTATTTTGG-
ATTGAAGCCAAT-ATGAG-30) or (iii) the 80 bp HindIII–
SmaI fragment from p21 to 192 were 50 32P-end-labeled as
described (30) and used as probes in the electrophoretic
mobility shift assays (EMSAs). Approximately 3 · 10
4
c.p.m. labeled DNA was incubated for 5 min at room temp-
erature with nuclear extracts in the presence of poly(dI:dC)
(Amersham) and 50 mM KCl in buffer D (10 mM HEPES,
10% v/v glycerol, 0.1 mM EDTA, 0.25 mM phenylmethylsul-
fonyl ﬂuoride). DNA–protein complexes were separated by
electrophoresis on native 4 or 6% polyacrylamide gels run
in Tris/glycine buffer at 4 C, as described previously (30).
Competition experiments in EMSA were conducted as
described above except that up to 500-fold molar excesses
of the following unlabeled double-stranded oligonucleotides
were added to the reaction mixture as unlabeled competitors:
p21.1, or derivatives of p21.1 that bear mutations (bold,
small letters) into either the 50 (in p21.1m50:5 0-GCCTGCT-
aaAACTCGGCCAGGCTCAGCTGGCTCCGCGCTGG-30)
or the 30 NFI half-site (in p21.1m30:5 0-GCCTGCTG-
GAACTCGattAGGCTCAGCTGGCTCCGCGCTGG-30), or
mutated into both half-sites (in p21.1m5030:5 0-GCCTGC-
TaaAACT-CGattAGGCTCAGCTGGCTCCGCGCTGG-30),
p21.2 (50-GCCTGCTGGAACTCGGCCAGGC-TC-30) and
p21.3 (50-CAGCTGGCTCCGCGCTGG-30) which corre-
spond to each half of the p21.1 sequence, CTF/NFI, AP1
(50-GATCCCCG-CGTTGAGTCATTCGCCTC-30) and Sp1
(50-GATCATATCTGCGGGGCGGG-GCAGACACAG-30).
EMSA supershift experiments were conducted as above
except that 3 ml of either a pre-immune serum, or a polyclonal
antibody that can recognize all isoforms of NFI (sc-5567,
Santa Cruz Biotechnology, Santa Cruz, CA, USA) was incu-
bated with the proteins for 5 min prior to the addition of the
probe.
Methylation interference
The 83 bp SmaI–HindIII fragment from the p21–192 plasmid
that covers p21 promoter sequences from  110 to  192 was
50 end-labeled at the  110 position (top strand) and partially
methylated with DMS as described (31). Approximately
3 · 10
5 c.p.m. methylated, labeled probe was incubated with
100 mg crude nuclear proteins from HeLa cells in the pres-
ence of 1 mg poly(dI:dC) in buffer D and DNA–protein com-
plexes were separated by electrophoresis through a 6% native
polyacrylamide gel in Tris-glycine buffer. Following electro-
phoresis, the DNA–protein complexes were visualized by
autoradiography and isolated by electroelution as described
(32). The isolated labeled DNA was then treated with piper-
idine (33) and further analyzed on a 6% sequencing gel.
DNase I in vitro footprinting
The 228 bp XbaI/KpnI DNA fragment spanning the p21 pro-
moter sequence from position  192 to +36 was 50 end-
labeled and used as a probe in DNase I footprinting. DNase
I digestion was performed in DNase I buffer (34) by incubat-
ing 4 · 10
4 c.p.m. labeled probe with 75 mg crude nuclear
proteins from HSF cells. Further analysis of the digested
products onto polyacrylamide sequencing gels was done as
described previously (35).
SDS–PAGE and Western blot
One volume of sample buffer (6 M urea, 63 mM Tris
[pH 6.8], 10% [vol/vol] glycerol, 1% SDS, 0.00125% [wt/
vol] bromophenol blue and 300 mM b-mercaptoethanol)
was added to 15 mg proteins before they were size fraction-
ated on a 10 or 12% SDS–polyacrylamide minigel and
electro-transferred onto a nitrocellulose membrane o/n at
4 C. The blot was then washed once (5 min) with TS buffer
(150 mM NaCl and 10 mM Tris–HCl [pH 7.4]) and once
(30 min) in TSM buffer (TS buffer plus 5% [wt/vol] fat-
free powdered milk and 0.1% Tween-20). Then, a 1:5000
dilution of the NFI antibody in TSM buffer was added to
the membrane and incubation proceeded for at least 90 min
at 22 C. The blot was then washed four times in TSM
buffer and incubated an additional 90 min at 22 Ci na
1:5000 dilution of a peroxidase-conjugated goat anti-rabbit
immunoglobulin G (Jackson Immuno-research, Biocan
Scientiﬁc, Mississauga, ON, Canada). The membrane was
successively washed in TSM (twice, 5 min each) and TS
(twice, 5 min each) before immunoreactive complexes
were revealed using western blot chemiluminescence
reagents (Renaissance, NEN Dupont, Boston, MA) and
autoradiographed.
Transient transfections and CAT assay
Primary cultured HSFs and the established tissue culture cell
lines HeLa and GH4C1 were all transiently transfected with
the p21-CAT recombinant constructs (p21–2300, p21–192
and its mutated derivatives p21–192 mNFI, p21–124) by
the calcium phosphate precipitation method as described
(36), using 15 mg of the test plasmid and 5 mg of the
human growth hormone (hGH) gene-encoding plasmid
pXGH5 (37). CAT activities were measured as described pre-
viously (38) and normalized to hGH secreted into the culture
medium, which was assayed using a radioimmunoassay kit
(Medicorp, Montre ´al, Que ´bec, Canada). Each single value
is expressed as 100 · (% CAT in 4h)/100 mg protein/ng
hGH. To be considered signiﬁcant, each individual value
needed to be at least 3-fold the value of the background
level caused by the reaction buffer used (usually correspond-
ing to 0.15% chloramphenicol conversion). To compare the
groups, Student’s t-test was performed. Differences were
considered to be statistically signiﬁcant at P < 0.05. All
data are expressed as mean ± SD.
Chromatin immunoprecipitation assays
The ChIP analyses were conducted as previously described
(39). Brieﬂy, HSFs were grown on 150-mm tissue culture
dishes to  75% conﬂuence in complete DMEM, or in FBS-
depleted DMEM for periods of time ranging from 48 to 72 h.
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10 min, harvested, and chromatin immunoprecipitated with
1 mg polyclonal antibodies directed against the Sp1 (sc-59;
Santa Cruz Biotechnology), Sp3 (sc-644; Santa Cruz Biotech-
nology), NFI and E2F1 (sc-193·; Santa Cruz Biotechnology)
transcription factors (Santa Cruz Biotechnology, Inc. Santa
Cruz, CA). The resulting DNA was analyzed by PCR using
a pair of primers (p21–279U: 50CAGATTTGTGGCTC-AC-
TTCGTGG-30 and p21+223L: 50AGAAACA-CCTGTGAA-
CGCAGCAC-30) spanning the entire p21 gene promoter
area from nt –279 to +223. As a negative control, each
ChIP sample was also subjected to PCR using primers
(p21–2587U: 50AATTCCTCTGAAAGCTGACTGCC30 and
p21–2132L: 50AGGTTTACCTGGGGTCTTTA-GA-30) spe-
ciﬁc to a region located  2 kbp upstream from the p21
promoter.
RNAi assays
Silencer
TM negative control (id #4611, #4613, #4615), and
Silencer
TM pre-designed siRNA duplexes against NFI-A (id
#115686, #115687, #144076), NFI-B (id #115688, #115689,
#115690), NFI-C (id #215174, #215173) and NFI-X (id
#115298, #115297, #3296) were purchased from Ambion,
Inc. (Austin, TX, USA) and used according to
manufacturer’s speciﬁcations. Brieﬂy, 2.5 mg of all three
siRNAs directed against NFI-A mRNA were combined and
transfected in triplicate into HSFs cultured to sub-conﬂuence
onto 39-mm tissue culture dishes (1 · 10
6 cells per dish at
start) by the calcium phosphate precipitation method along
with 10 mg of the appropriate plasmid construct (p21–124,
p21–192, p21–192-mNFI, p21–2300 and p21–2300-mNFI).
Cells were harvested 48 h following the addition of fresh
medium and processed as mentioned above for the CAT
assay.
RESULTS
In vivo footprinting of the p21 gene promoter
by LMPCR
In an attempt to identify the transcription factors that regu-
late p21 gene transcription, we performed in vivo footprinting
analyses of the proximal promoter region from the p21 gene
in normal, proliferating primary cultures of HSFs by exploit-
ing the LMPCR procedure (24). Footprint analyses were per-
formed on the p21 promoter region covering both strands
from position  220 to +40 relative to the p21 mRNA start
site. Many protected and hyper-reactive sites were detected
along the area from the p21 promoter that bear a putative
NFI target site, on both the top and bottom strands. As
shown on Figure 1A to 1C (and also summarized in
Figure 1D), the comparison of the band intensity from the
in vivo and in vitro treatments revealed many protected
and hypersensitive nucleotides. Consistent with studies that
reported binding of TBP to the TATA-box of other active
gene promoters in different human cells (40,41), we also
observed protected residues along the TATA-box of the
p21 gene (from nt  28 to  14) as shown on Figure 1B
(and summarized on Figure 1D). The DNase I protection
extended many base pair beyond the 30 end of the TATA-
box that is typical of the association of other members of
the holoenzyme with TBP. In addition, four of the six puta-
tive Sp1 binding sites reported to be required for p21 gene
expression under basal and inducible conditions [(4,42); see
discussion for details] were indeed protected from methyla-
tion by DMS. Two additional p21 promoter regions that
revealed DNA–protein interactions were also identiﬁed by
LMPCR. The ﬁrst corresponds to the DNA target site for
the transcription factor E2F1 ( 84 to  80) that has already
been shown to up-regulate transcription of the p21 gene
[(43,44); see discussion for details]. The second protected
area extends from position  161 to  138 and encompasses
a potential binding site for NFI ( 161 to  149). This large
DNA–protein interaction interface also extended 10 bp
beyond the 30 end of the NFI site, from  148 to  138. How-
ever, search using computer databases for the identiﬁcation of
transcription factors target sites could not suggest any known
putative transcription factor that could interact with this
speciﬁc DNA segment from the p21 promoter.
Proteins from the NFI family bind the
 161/ 149 sequence of the p21 promoter
Both competition and supershift experiments in EMSA
were conducted to demonstrate whether NFI possesses the
ability to bind the  161/ 149 region from the p21 gene
(Figure 2). Incubation of a labeled probe (p21.1) bearing
the entire footprinted region from positions  167 to  127
(Figure 2A), with nuclear proteins from primary cultured
HSFs (Figure 2B) yielded a diffuse pattern of DNA–protein
complexes (lane 2) identical to that reported previously for
NFI (45–47). The formation of these DNA–protein com-
plexes was almost completely abolished by the addition of
a 150-fold molar excess of an unlabeled competitor oligo-
nucleotide bearing the consensus sequence for CTF/NFI
(lane 8). Formation of these complexes was also prevented
when either the p21.1 (lane 3) or the p21.2 double-stranded
oligonucleotides (lane 4), both of which has the NFI-binding
site from the p21 promoter (Figure 2A), were used as com-
petitors (Figure 2B). However, the p21.3 oligonucleotide,
which is deleted from the NFI binding site (Figure 2A),
was unable to compete for the formation of the p21.1/protein
complexes (data not shown). This result suggests that the
 127 to  144 p21 sequence, which bear the protected resi-
dues identiﬁed immediately 30 from the NFI site in the
p21 promoter, is not required for NFI binding and is likely
recognized by a yet unknown nuclear protein. Derivatives
of the p21.1 oligonucleotide that bear mutations either in
the 50 (in p21.1m50) or the 30 (in p21.1m30) half-site of NFI
could still compete, although not as efﬁciently as the
wild-type p21.1 oligomer, for NFI binding to the labeled
probe (28% reduction with p21.1m50 (lane 5) and 43% with
p21.1m30 (lane 6) as evaluated using Biorad Quantity
One software) indicating that NFI possesses the ability to
bind to each single half-site from the p21 NFI site in vitro.
The oligomer bearing both mutated sites (p21.1m5030)
was unable to compete for the formation of this complex in
EMSA (lane 7). Competitors bearing the target sequences
for the unrelated transcription factors AP1 (lane 9) and Sp1
(lane 10) were unable to compete for the formation
of the shifted complexes yielded by the HSFs nuclear
extract, a further evidence that the complexes detected
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by NFI.
To validate the identity of NFI as the transcription factor
binding the p21.1 labeled probe, supershift experiments
were conducted using a polyclonal Ab directed against
an N-terminal epitope shared by all members of the NFI
family. The NFI Ab recognized at least one of the proteins
binding the p21.1 probe and led to the formation of a larger
supershifted complex (SC in Figure 2B, lane 12). This new
complex did not result from the non-speciﬁc recognition of
the labeled probe by the NFI Ab or by an unrelated serum
protein as neither condition (Figure 2B, lanes 13 and 14)
could yield the supershifted complex seen when the NFI
Ab is incubated with the p21.1 probe in the presence of
nuclear proteins (Figure 2B, lane 12). Altogether, these
results suggest that NFI binds the p21 promoter through its
Figure 1. Genomic footprinting of the human p21 gene promoter. The region shown was analyzed with primer set 1, to reveal the bottom strand sequence from nt
 167 to  85 (A), and the primer set 2, to reveal the upper strand sequence from nt  114 to  12 (B) and nt  167 to  137 (C) relative to the transcription
initiation site. Lane 1, 8 and 10: LMPCR of naked DNA purified from primary cultures of HSFs treated in vitro (t) with DMS (lane 1), UVC (lane 8) or DNase I
(lane 10). Lanes 2, 7 and 9: LMPCR of DNA purified from HSFs treated in vivo (v) with DMS (lane 2), UVC (lane 7) or DNase I (lane 9) prior to DNA
purification. Lanes 3–6: Maxam-Gilbert sequencing. DMS protected and hypersensitive guanines are indicated by opened and closed circles, respectively, on
each side of the autoradiograms, whereas UVC protected and hypersensitive sites are indicated by opened and closed squares. The DNase I protected and
hypersensitive sites are indicated by   and +, respectively. (D) Summary of the in vivo DMS, UVC and DnaseI footprints identified along the  187 to  136
human p21 gene promoter. The position of the consensus sequence for the specified transcription factors is also indicated above the sequence.
6476 Nucleic Acids Research, 2006, Vol. 34, No. 22Figure 2. EMSA analysis of nuclear proteins from primary cultured HSFs interacting with the p21 NFI target site. (A) DNA sequence of the double-stranded
oligonucleotidesusedasprobesorcompetitorsintheEMSAexperiments.TheconsensussequenceforNFIisalsoindicatedforcomparisonpurpose(NFIcon).(B)The5 0
end-labeled p21.1 oligonucleotide was incubated with nuclear proteins (5 mg) from HSFs either alone (C; lane 2) or with a 150-fold molar excess of various unlabeled
competitoroligonucleotides(p21.1,p21.1m50,p21.1m30,p21.1m5030,p21.2,NFI,AP1andSp1;lanes3to10).FormationofDNA–proteincomplexeswasthenmonitored
by EMSA on a 6% native polyacrylamide gel. The position of multiple DNA–protein complexes corresponding to the recognition of the labeled probe by human NFI
proteins is indicated (NFI).The p21.1 probe wasalso incubated with 5 mg HSFsnuclear proteins either alone (C; lane 11) or in the presenceof either2 ml of a polyclonal
antibody directed against NFI (lane 12) or 2 ml of a mouse non-immune serum (NIS; lane 13). Formation of DNA–protein complexes was then monitored by EMSA as
above.Asanadditionalnegativecontrol,theprobewasalsoincubatedwiththeNFIAbintheabsenceofnuclearproteins(lane14).SC;supershiftedcomplexresultingfrom
the recognition of the NFI-p21 labeled probe complex by the NFI Ab. P: labeled probe with no added protein (lane 1). U: unbound fraction of the probe. (C) The p21.1
labeledprobe usedin B wasincubated with 5 mg nuclear proteins from HSFs either alone (lanes 1 and 8), or in the presence of increasing concentrations (5- to 500-fold
molar excesses) of unlabeled, double-stranded competitorsbearing the sequenceof eitherthe p21 NFI site (p21.1) or that of the high-affinity, NFI prototypicaltargetsite
(NFI).Formation of DNA–proteincomplexes wasthenmonitoredby EMSA as above.The position of theNFI complexis indicated along with that ofthe freeprobe(U).
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primary cultured HSFs.
The NFI target site from the p21 promoter differs from the
prototypical sequence by 3 nucleotides over the entire 15 bp
that constitutes this site (Figure 2A). Recently, Roulet et al.
(48) conducted a very elegant study in which they function-
ally validated a binding site predictor that could predict
the afﬁnity of a degenerated NFI site relative to that of the
prototypical NFI sequence. According to their mathematical
model, NFI is expected to bind the p21 NFI target site
with an afﬁnity of over 91% that normally yielded when it
binds the high-afﬁnity NFI prototypical (consensus) sequence
(which, in this case, is considered to correspond to an afﬁnity
of 100%). We therefore assessed the afﬁnity of NFI toward
both the p21 and the prototypical NFI target sites by incu-
bating crude nuclear proteins from HSFs with the p21.1
labeled probe in the presence of varying concentrations
(5- to 500-fold molar excesses) of either unlabeled p21.1 or
the NFI consensus oligomer. As shown on Figure 2C, the
unlabeled p21.1 oligomer was as efﬁcient as the prototypical
NFI-bearing oligonucleotide in competing for the formation
of the NFI complex in EMSA. This result provided evidence
that NFI binds to the p21 degenerated NFI site with an afﬁn-
ity undistinguishable from that obtained with the prototypical
NFI site.
Recognition of DNA target sites by transcription factors
might on occasion differ depending on whether the labeled
probe used in the EMSA is synthetic (as the double-stranded
oligonucleotide p21.1 used above) or derived from the gene’s
regulatory sequence. To further validate the results from the
EMSAs conducted using the p21.1 oligonucleotide, EMSA
experiments were repeated by using an 83 bp genomic frag-
ment obtained from the SmaI–HindIII digestion of the p21–
192 plasmid and covering the p21 promoter sequence from
positions  110 to  192 as labeled probe. For this speciﬁc
purpose, and to increase the sensitivity of the assay, we
used a carboxymethyl (CM)-Sepharose enriched preparation
of rat liver NFI-L (29) as the source of NFI protein. As
shown on Figure 3A (lane 2), NFI-L indeed bound to the
 110/ 192 p21 labeled probe very efﬁciently. Speciﬁcity
for the formation of the NFI complex was further demon-
strated by both competition experiments in EMSA (only the
NFI but not the unrelated Sp1 competitor oligonucleotide
could compete for the formation of the shifted complex;
Figure 3A, lanes 3 and 4, respectively) and supershift experi-
ments [Figure 3A; addition of the NFI Ab (lane 6) super-
shifted the NFI complex from its normal position on the gel
(NFI) to that corresponding to a complex with low elec-
trophoretic mobility in gel (SC)].
We next performed both DMS methylation interference
assays and DNase I footprinting in vitro in order to more pre-
cisely deﬁne the DNA target site bound by NFI along the
 110 to  192 p21 promoter fragment. As shown in
Figure 3B, methylated G residues that interfere with binding
of NFI to its target site in the p21 promoter in vitro also per-
fectly mapped within the site protected by NFI and deﬁned
through the use of the in vivo footprinting procedures (see
Figure 1). In vitro DNase I footprinting identiﬁed only a
short stretch of protected sequence ( 3 bp) that is contained
within the NFI site identiﬁed in vitro by DMS footprinting
and in vivo by LMPCR. The lack of DNase I break points
in the binding site of NFI, as revealed by the absence of
bands on the autoradiogram, did not allow the determination
of the entire sequence protected by the protein. This in vitro
result contrasts with the in vivo footprinting data for this
particular p21 promoter region as a larger protection could
be observed (extending over  14 bp; see Figure 1). We there-
fore conclude that NFI indeed possesses the ability to bind
efﬁciently to the p21 basal promoter both in vivo and
in vitro by interacting with a target site located between
positions  161 and  149.
NFI functions as a repressor of p21 promoter activity
and triggers G2-arrested cells into the S-phase of
the cell cycle
In order to assess the regulatory inﬂuence exerted by the p21
NFI site, DNA fragments spanning the p21 basal promoter
and extending from 50 position  192 up to either 30 positions
+36 (which include the NFI site) or –124 to +36 (in which the
NFI site has been deleted) was inserted upstream the CAT
reporter gene (Figure 4A) and transiently transfected into
either primary cultured HSFs or tissue culture cells (HeLa
and GH4C1). Deletion of the entire NFI site identiﬁed by
in vivo footprinting (in p21–124), yielded a signiﬁcant
increase in the activity of the CAT reporter gene upon trans-
fection of the three different types of cells used in this study
(3.1-, 2.9- and 2.3-fold increase in CAT activity relative to
the level directed by the p21–192 plasmid in HSFs, HeLa
and GH4C1 cells, respectively; Figure 4B). In order to prevent
undesirable regulatory effects that might have resulted from
the deletion of sequences nearby the p21 NFI site in the
p21–124 construct, the NFI site from the parental plasmid
p21–192 was also altered through site-directed mutagenesis.
The ﬁve residues identiﬁed through both DMS methylation
interference and LMPCR footprinting as the most important
for NFI binding out of the 15 bp that constitute the p21
NFI site were changed for As and Ts (the wild-type NFI
site 50-CTGGAACTCGGCCAG-30 was changed to 50-CTaa-
AACTCGattAG-30) to create the NFI-mutated construct
p21–192 mNFI. Consistent with the data from the deletion
analysis, mutation of the p21 NFI site in p21–192 mNFI
also yielded a substantial increase in CAT activity relative
to the unmutated, wild-type NFI-bearing construct p21–192
upon transfection of all cell types (8.5-, 2.3- and 3.1-fold
increase in HSFs, HeLa and GH4C1 cells, respectively),
further validating the results from the deletional analysis
(Figure 4B).
To further demonstrate the negative regulatory inﬂuence
of NFI on the p21 promoter, p21–192 was co-transfected
along with expression plasmids encoding high level of
expression of each of the NFI isoforms into HCT116 cells.
This cell line proved to be particularly interesting as it
expresses very little NFI protein in Western blot analyses,
unlike Sp1, which is abundantly expressed in these cells
(Figure 5A). Because HCT116 cells can be easily growth
arrested in the G2-phase of the cell cycle by the addition
of doxorubucin, p21–192 was therefore transfected either
alone or in the presence of each of the NFI expression plas-
mid (NFI-A, -B, -C and -X) in growth-arrested HCT116 cells.
Part of the transfected HCT116 cells were used for the mea-
surement of the CAT activity while the remaining cells were
6478 Nucleic Acids Research, 2006, Vol. 34, No. 22used to monitor cell cycle progression of the doxo-growth-
arrested cells by FACS analyses. Transfection of HCT116
cells with the NFI expression plasmids revealed that all
four NFI isoforms could reduce the activity of the p21–192
construct (up to 3.5-fold repression with NFI-X;
Figure 5B). Furthermore, co-transfection of p21–192 along
with the combination of NFI-B, -C and -X brought down
p21 promoter function further to a 5-fold repression. Cultur-
ing HCT116 cells in the presence of doxorubicin indeed
arrested the cells primarily into the G2-phase of the cell
cycle, with  3% of the cells in the S-phase (compare 1st
and 2nd columns on Figure 5C) but did not affect the
negative regulatory inﬂuence of the NFI isoforms on the
activity of the p21 promoter (results not presented). Interest-
ingly, while over-expressing NFI-A, -C and -X substantially
reduced the proportion of the cells committed into growth
arrest (down to 1% with NFI-A), over-expression of NFI-B
considerably increased those in the S-phase (up to  9%).
Transfection of doxorubicin-treated HCT116 cells with
the combination of the NFI-B, -C and -X dramatically
reduced the cells remaining in S-phase from 2.7 ± 2.0 to
0.4 ± 0.7.
Figure 3. In vitro DMS and DNase I footprinting of NFI binding to the p21 promoter. (A) The 50 end-labeled 83 bp SmaI–HindIII fragment from the p21–192
plasmid that covers p21 promoter sequences from  110 to  192 was incubated with 2 mg nuclear proteins from a CM-Sepharose-enriched preparation of rat liver
NFI in the presence of either no (C; lanes 2 and 5) or a 150-fold molar excess of unlabeled competitor oligomers (NFI or Sp1; lanes 3 and 4, respectively)
Formation of DNA–protein complexes was then monitored by EMSA on a 4% native polyacrylamide gel. The position of the NFI/p21–192 DNA–protein
complex is indicated (NFI). The  110/ 192 labeled probe was also incubated with 2 ml of the NFI Ab to monitor the formation of the NFI/NFIAb/p21 protein–
protein–DNA supershifted complex (SC in lane 6). P: labeled probe with no added protein (lane 1). U: unbound fraction of the labeled probe. (B) The labeled
probe used in A was methylated with DMS and incubated with CM-Sepharose-enriched NFI before separation of the DNA–protein complex by EMSA. Both the
labeled DNA from the NFI complex (NFI in panel A) and the unbound fraction of the probe (U in panel A) were isolated and further treated with piperidine
before being analyzed on a 8% polyacrylamide sequencing gel. The DNA sequence from the p21 promoter that includes the protected G residues (full and half
circles correspond to fully and partly protected G residues, respectively) is indicated along with its positioning relative to the p21 mRNA start site. The p21 NFI
target site is also indicated (box). (C) A 228 bp DNA fragment spanning p21 promoter sequences from position  192 to +36 was 50 end-labeled and incubated
with 75 mg CM-Sepharose-enriched NFI before being digested with DNase I. The position of the NFI site protected from digestion by DNase I is shown (shaded
box) along with that of the p21 NFI site identified by in vivo footprinting (full line box). G: Maxam and Gilbert ‘G’ sequencing ladder; C: labeled DNA digested
by DNase I in the absence of proteins.
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of p21 gene transcription
P21 being cell cycle regulated, we investigated the NFI
inﬂuence on p21 gene transcription upon transfection of
both the wild-type p21–192 construct or its NFI-mutated
derivative p21–192 mNFI into primary HSFs grown in
serum-free medium, a condition under which p21 is known
to be highly expressed (49–51). As expected, basal p21 pro-
moter activity increased considerably upon serum starvation
(about 3-fold for p21–192 and 4-fold for p21–192 mNFI;
Figure 6A). Under the experimental conditions used to con-
duct this transfection, which differ slightly from those used
above in Figure 4 (see Experimental Procedures), mutation
of the NFI site yielded an 11-fold increase in CAT activity
when HSFs were maintained in complete medium. However,
p21 promoter activity increased further up to 17-fold in
serum-starved HSFs. This increase in p21 promoter activity
when cells are maintained under serum-free condition corre-
lated with a signiﬁcant decrease in NFI binding in EMSA
(Figure 6B) when ﬁbroblasts are deprived of serum for vari-
ous periods of time (24, 48 and 72 h), despite that no altera-
tion in the absolute amount of the NFI protein is observed
in Western blot (Figure 6C). Indeed, while extracts from
HSFs grown in the presence of serum yielded a very clear
and intense NFI-labeled probe DNA–protein complex in the
EMSA (Figure 6B, lane 2), culturing them under serum star-
vation for various periods of time (48, 60, 66 and 72 h)
resulted in a more diffused, strongly reduced NFI signal
(Figure 6B, compare lanes 4, 6, 8 and 10 with lane 2). This
reduction in NFI binding could not be accounted for from
the degradation of NFI as no signiﬁcant quantitative nor
qualitative changes are observed in the total amount of NFI
as revealed by Western blot (Figure 6C). Besides, maintain-
ing HSFs under serum-free condition up till 72 h did not
committed the cells into apoptosis as poly(ADP-ribose)
polymerase-1 (hPARP-1), a 113-kDa DNA repair enzyme
whose cleavage by caspase-3 into degradation products of
89- and 22-kDa (of which the larger is efﬁciently recognized
by the C-2–10 mAb) is recognized as an early marker of apop-
tosis (52,53), remained entirely intact during serum starvation
(Figure6D).Thisisfurthervalidatedbythefactthatproteinsin
the high molecular range showed no evidence of degradation
upon Coomassie blue staining on gel (Figure 6E). In addition,
HSFsexhibitedanormalcellmorphologyunderphase-contrast
microscopywithnosignofapoptosis,evenwhenthecellswere
maintained for 72 h without serum (Figure 6F).
NFI binds the p21 promoter in vivo in dividing
but not serum-starved HSFs
The binding of NFI to the p21 gene promoter area was further
examined in vivo in HSFs by ChIP assays. As a control, ChIP
was also conducted on other transcription factors, such as
Sp1, Sp3 and E2F1, also reported to bind the p21 basal pro-
moter. Primers that spanned the entire p21 promoter from
 279 down to +223 relative to the p21 mRNA start site
were selected for the assay. Antibodies against Sp1, Sp3
and NFI all enriched the p21 promoter sequences in HSFs
grown in complete, serum-containing medium, indicating
that this genomic area is bound in vivo by these transcrip-
tion factors (Figure 7A). In contrast, only the Sp3 and
E2F1 antibodies enriched the p21 promoter in HSFs main-
tained under serum starvation for 72 h, relative to the ‘no
antibody’ control sample. These results suggest that Sp1,
Sp3 and NFI are bound to cis-acting elements present on
the p21 promoter in the in vivo chromatin conﬁguration of
HSF cells during the dividing phase of the cell cycle (basal
level of p21). Upon serum starvation (where high levels of
p21 expression are observed), binding of both Sp1 and
NFI were completely abrogated. Interestingly, while the
level of Sp3 binding to the p21 promoter remained unaff-
ected by serum starvation, that of E2F1, initially undetectable
in actively growing cells, was found to bind weakly in serum-
deprived HSFs. The signiﬁcant occupancy of NFI in relation
to the ‘input’ (Figure 7B), suggest a critical role for this
transcription factor on the p21 gene regulation. These results
demonstrate that NFI binds the p21 promoter area in vivo
in actively growing, but not serum-starved, growth-
arrested HSFs.
Suppression of NFI expression by RNAi alleviates
p21 repression
Evidence that NFI functionally represses p21 promoter activ-
ity was further examined through the suppression of the
Figure 4. Transient transfection analysis. (A) Schematic representation of the
plasmids used. The NFI target site from the p21 promoter is shown. Numbers
indicate positions relative to the p21 mRNA start site. (B) The plasmids
shown in A were transfected into HSFs, as well as in the tissue culture cell
lines GH4C1 and HeLa. Cells were harvested and CAT activities determined
and normalized to secreted hGH. *CAT activities that are statistically
different from those obtained with the p21–192 construct (P < 0.05; paired
samples, t-test).
6480 Nucleic Acids Research, 2006, Vol. 34, No. 22endogenous NFI transcript by RNAi (Figure 7C). Because
HeLa cells are much easier to culture and are transfected
with a higher efﬁciency, they were selected over HSFs forcon-
ductingtheRNAiassays.Recombinantconstructsbearingvari-
ous lengths from the p21 promoter (up to 50 positions  124,
 192and 2300)wereco-transfectedwithandwithoutacom-
binedpoolofsiRNAsdirectedagainstNFI-A,-B,-Cand-X.As
expected, the P21–124 construct lacking the NFI binding site
yielded a promoter activity higher than the NFI-bearing con-
structs p21–192 and p21–2300, which are both under the nega-
tive regulatory inﬂuence of NFI. Co-transfection of these
constructs along with the NFI siRNAs substantially released
repression by NFI for both p21–192 (3-fold increase) and
p21–2300(near7-foldincrease).Again,mutatingtheNFIbind-
ing site in p21–192 (p21–192 mNFI) strongly increased CAT
activity in HeLa cells (by  8-fold). However, while inhibition
of endogenous NFI through RNAi considerably increased
the activity of the unmutated, wild-type p21–192 construct
(3-fold increase) it had no such inﬂuence when the NFI site
is mutated in p21–192 mNFI (which yielded a weak 27%
reduction in p21 promoter activity).
DISCUSSION
Cyclin-dependent kinase inhibitor p21 plays a key function in
cell cycle arrest at the G1/S checkpoint in response to DNA
damage, and is involved in the assembly of active cyclin-
kinase complexes especially cyclin D-Cdk4/6. Transcription
of the p21 gene relies on the control of numerous regulators
of which many still have to be identiﬁed. In the present study,
we precisely mapped, through both in vivo (LMPCR) and
in vitro (DMS and DNase I footprinting) approaches, a target
site for the transcription factor NFI in the basal promoter of
the human p21 gene that proved to function as a powerful
repressor of p21 gene transcription in both non-damaged
and proliferating primary cultures of human ﬁbroblasts and
established tissue culture cells.
To our knowledge, no evidence regarding a regulatory
function exerted by NFI on the transcription of the p21
gene has ever been published until now. We demonstrated
that members of the NFI family could bind a target site on
the p21 basal promoter located between positions  161 and
 149, and considerably repress its transcription in a variety
Figure 5. Influence of NFI over-expression on p21 promoter activity in growth-arrested HCT116 cells. (A) Crude nuclear extracts were prepared from both
HCT116 and HeLa cells (used as a control) and examined for expression of Sp1 and NFI in Western blot analyses. (B and C) The p21–192 recombinant construct
was co-transfected with the empty vector pCH (+EV), or with expression plasmids encoding each of the NFI isoforms, either individually (+NFI-A, -B, -C and
-X) or in combination (+NFI-BCX), in doxorubicin, growth-arrested HCT116 cells. Cells were collected 48 h later and used either for the measurement of the
CAT activity (panel B) or to determine the proportion of the cells engaged in the S-phase of the cell cycle by FACS analyses (panel C).
Nucleic Acids Research, 2006, Vol. 34, No. 22 6481of cells. Although each of the four NFI isoforms were found
to contribute to this repression, NFI-X turned out to be the
most effective. Intriguingly, each member from this family
exerted very speciﬁc inﬂuences on the growth properties of
the cells by either restricting or promoting progression
of the cells into the S-phase from the cell cycle. Indeed,
over-expression of NFI-A, -C and -X reduced the number
of cells remaining in the S-phase in HTC116 cells that have
been growth arrested with doxorubicin, whereas over-
expressing the NFI-B isoform triggered more cells to enter
the S-phase, thereby establishing the biological signiﬁcance
for the regulatory inﬂuence of NFI on cell cycle progression.
Figure 6. Influence of serum starvation on NFI binding and p21 promoter function in vitro.( A) The p21–192 construct and its NFI-mutated derivative p21–192
mNFI were transfected into HSF grown either in complete (+FBS) or serum-free DMEM ( FBS) for 72 h. Cells were then harvested and CAT activities
determined and normalized to secreted hGH. Asterisks indicate CAT activities that are statistically different from those obtained with the p21–192 construct
(P < 0.05; paired samples, t-test). (B) A double-stranded oligonucleotide bearing the high-affinity binding site for human CTF/NFI was incubated with 5 mg
proteins from HSFs grown for various periods of time post-transfection (48, 60, 66 and 72 h) in complete (+FBS) or serum-deprived DMEM ( FBS). Formation
of DNA–protein complexes was then monitored by EMSA on a 6% native polyacrylamide gel. The position of multiple DNA–protein complexes corresponding
to the recognition of the labeled probe by human NFI is indicated (A and B). Extracts from each condition were also incubated either alone ( ; lanes 2, 4, 6, 8 and
10) or with 2 ml of the NFI Ab (+; lanes 3, 5, 7, 9 and 11). P: labeled probe with no added protein (lane 1); U: unbound fraction of the labeled probe. (C) Western
blot analysis of NFI in nuclear extracts prepared from HSFs cultured in complete DMEM (+FBS) or FBS-free DMEM ( FBS) for 48–72 h. (D) Western blot
analysis of PARP-1 expression in HSFs cultured in complete DMEM (+FBS) or FBS-free DMEM ( FBS) for 48–72 h. Nuclear extracts from HL60 cells
cultured in the absence and presence of the apoptosis inducer VP16 were also loaded in lanes 6 and 7 as negative and positive controls, respectively. (E)1 5mg
nuclear proteins from each of the extracts used above were loaded on a 10% SDS–polyacrylamide gel and stained with Coomassie blue for comparative purpose.
(F) Phase-contrast images of HSFs cultured in complete DMEM (+FBS) or FBS-free DMEM ( FBS) for 48–72 h. Magnification, ·200.
6482 Nucleic Acids Research, 2006, Vol. 34, No. 22Figure 7. Chromatin immunoprecipitation of NFI and RNAi assays in HSFs. (A) ChIP assays were performed on HSFs in an exponential state of growth or after
72 h of serum starvation. Chromatin was isolated and immunoprecipited with antibodies directed against the transcription factors Sp1, Sp3, NFI and E2F1. PCR
of the p21 gene promoter was then carried out on the ChIP samples along with a ‘no antibody’ control (No Ab) that contains chromatin but no antibody, an
‘input’ sample corresponding to 0.2% of the total input chromatin, and a ‘mock’ sample that does not contain chromatin. PCR amplification of a gene segment
located  2000 bp upstream from the p21 promoter was also conducted on the same sample as a negative control for all immunoprecipitates. (B) Graphical
representation of the amount of specific PCR products expressed as the percentage of antibody binding versus the amount of PCR product obtained using a
standardized aliquot of input chromatin. The signal in the no-antibody lane corresponds to the non-specific binding background and was subtracted from each
sample. (C) RNAi was performed using a combination of siRNA complementary to the NFI-A, -B, -C and -X transcripts. The p21 promoter-bearing recombinant
constructs p21–124, p21–192 and p21–2300, and the derivative from p21–192 that comprise a mutated NFI site (p21–192 mNFI) were transfected together with
either the siRNA silencer negative control or with the combination of NFI siRNA duplexes (siNFI) into subconfluent HeLa cells. Cells were harvested and CAT
activities determined. *CAT activities that are statistically different from those obtained with the p21 promoter constructs transfected solely with the siRNA
silencer negative control (P < 0.05; paired samples, t-test).
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recently demonstrated that mutation of the NFI sites present
in the promoter of the adenine nucleotide translocase-2
gene (ANT2) totally annihilated the growth-arrest properties
of NFI in NIH3T3 cells. Most interestingly, they attributed
these growth-arrest properties of NFI to the NFI-A, -C and
-X isoforms but not NFI-B as the former were all found to
repress expression of an ANT2-driven reporter gene con-
struct, whereas NFI-B activated it. Members from the NFI
family can either repress or activate their target genes
depending on the cell type or promoter context. This means
that although all NFI isoforms were found to repress to vary-
ing degrees the transcription directed by the p21 promoter in
HCT116 cells, yet they may activate transcription of other
genes in the same cell that may or may not be related to
cell growth. For instance, NFI has been shown to activate
expression of p53 (55) and gadd153 (56), both of which
play key roles in growth arrest of damaged or environmen-
tally stressed cells. Paradoxically, NF1-X1 was identiﬁed as
one of three genes (together with c-myc and MDM2) that pre-
vent TGFb-induced growth arrest (57). Therefore, while all
NFI isoforms clearly repress p21 gene expression in HCT116
cells, NFI-B might as well regulate expression of additional,
cell-growth related genes that are not under the inﬂuence of
the other NFI isoforms. This differential property of NFI-B
may rely on its ability to recruit either co-repressors or co-
activators that are distinct from those recruited by other
NFI proteins. For instance, of all the NFI isoforms, only
NFI-B has been found to activate whey acidic protein (WAP)
gene expression in cooperation with STAT5A and the gluco-
corticoid receptor (GR) in JEG-3 cells (58). Most interest-
ingly, NFI-B deﬁcient mice have been shown to die early
after birth and display severe lung hypoplasia (59), lung
development being arrested at the late pseudoglandular
stage. These results suggest that NFI-B is most likely required
for normal lung cell proliferation in order to ensure proper
lung development. It is noteworthy that the in vivo footprint
identiﬁed in the present study extends 10 bp beyond the
30 end of the NFI consensus site (from  148 to  138). A
search conducted using databases for the identiﬁcation of
transcription factor target sites failed to identify any known
nuclear protein that may interact with the  148/ 138 p21
sequence. The presence of additional co-factors that can
bind DNA in vivo but not in vitro, as well as structural events,
such as DNA folding, could explain the detection of the pro-
tected residues located downstream from the  161 to  149
NFI site. Indeed, the RNAi experiments conducted in this
study (Figure 7C) suggested that other DNA binding proteins
might contribute to the appropriate transcription of the p21
gene by interacting somewhere along the  124/ 148 seg-
ment from the p21 promoter as the p21–124 construct did
not mimic levels achieved with the p21–192 that bears muta-
tions in the  161/ 149 NFI site. Besides, reducing the
endogenous level of NFI through RNAi is also likely to con-
siderably alter the transcription of many genes in the trans-
fected cells. Some of them may as well encode
transcription factors other than NFI that also participate to
the cascade of regulatory events required to ensure appropri-
ate transcription of the p21 gene. Further works will be
required in order to determine the precise identity of such cis-
acting transcriptional regulators and whether their regulatory
inﬂuences are mediated through their interaction with
the  148/ 138 area from the p21 promoter.
The NFI family of transcription factors is made-up of four
protein subtypes (NFI-A, -B, -C and -X) (60), each encoded
by a different gene, that can form either homo- or het-
erodimers. The large diversity of this family of proteins, for
which 19 isoforms have been described to date [reviewed in
(61)], rely on the fact that each individual NFI mRNA tran-
script is subjected to alternative splicing (33,62). Members
from the NFI family have been shown to function either as
repressors (35,46,56) or activators (63,64) of gene transcrip-
tion. Through interactions with weak binding sites, NFI may
also regulate gene expression by its ability to either cooperate
or compete with many transcription factors (35,65). Con-
sidering the negative inﬂuence exerted by NFI on p21 gene
transcription, we propose that NFI may act in cooperation
with other nearby co-activators or transcription factors to
restrict the expression of the p21 gene throughout the cell
cycle progression while DNA is undamaged. NFI was
reported to interact with and antagonize Sp1, which result
in the down-regulation of the platelet-derived growth factor
(PDGF)-A gene expression (65). Interestingly, in vivo foot-
printing analysis of the p21 promoter also revealed DNA–
protein interactions at four of the six putative consensus
binding sites reported for Sp1 (4). Besides NFI and Sp1,
these in vivo analyses also identiﬁed protections at target
sites for nuclear proteins, such as E2F1 (Figure 1) that have
already been reported to bind the p21 proximal promoter.
Members from the E2F family of transcription factors play
a crucial role in the transactivation of G1/S transition speciﬁc
genes (66). Previous studies already demonstrated the
involvement of E2F1 in the p53-independent activation of
p21 (43,44).
Results from the ChIP analyses revealed variations in the
pattern of p21 promoter occupancy by the transcription fac-
tors Sp1, NFI and E2F1 between actively growing and
serum-starved, quiescent HSFs. Indeed, whereas both Sp1
and NFI but not E2F1 substantially bind the p21 promoter
in proliferating cells, HSFs grown under serum deprivation
completely lost p21 promoter recognition by both Sp1 and
NFI but gained binding of E2F1. The relative occupancy of
the p21 promoter by NFI in vivo clearly exceeded that of
both Sp1 and Sp3 in proliferating HSFs, thereby favoring
repression rather than activation of p21 transcription. On
the contrary, the lack of any NFI binding in serum-starved
cells combined to the recognized positive inﬂuence of both
Sp3 and E2F1 as both factors were shown to bind the p21
promoter under this condition, is consistent with the increased
expression of p21 reported when cells progress toward
growth arrest (44,67).
Interestingly the presence of Sp3, whose binding to the p21
promoter does not change with alterations in the proliferative
state of the cells, raised the interesting possibility that most
of the Sp1 target sites identiﬁed in the p21 promoter might
became occupied by Sp3 under serum deprivation as both
transcription factors have been reported to bind the same
GC-rich target sites (67). It is noteworthy that Sp1/Sp3
share extensive structural and sequence homology (68), and
often cooperate in activating gene transcription (69–71).
The presence of Sp3 in HSFs grown with or without
serum suggests that p21 is constitutively activated by this
6484 Nucleic Acids Research, 2006, Vol. 34, No. 22transcription factor and that ﬁne tuning of p21 transcription is
ensured by subtle variations in the ability of nuclear repres-
sors such as NFI to interact with its corresponding target
site in the p21 promoter. Our results are consistent with
those published by other groups who demonstrated that while
basal transcription of p21 is regulated by both Sp1 and Sp3 in
cultured primary mouse keratinocytes, only Sp3 contributes
to the calcium-induced p21 promoter activity (67).
The identiﬁcation of each of the nuclear proteins yielding
the new protected sites identiﬁed in this study as well as
the precise regulatory function they play will be required to
assess the precise mechanisms that modulate p21-dependent
regulation of cell cycle progression. We must now look
upon NFI as a new and central player in the molecular
mechanisms regulating p21 expression during cell cycle pro-
gression. The relationship between NFI and other transcrip-
tion factors such as p53, Sp1, Sp3 and E2F1 that also bind
the p21 promoter will be of a particular interest and
should prove to be particularly fascinating regarding p21
gene regulation.
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